Immunome (IMNM) Assets Average (2020 - 2026)
Immunome's (IMNM) quarterly Assets Average came in at $651.5 million in Q1 2026, up 123.52% YoY from $291.5 million in Q1 2025, and up 32.61% on a QoQ basis from $491.3 million in Q4 2025.
Immunome (IMNM) Assets Average (2020 - 2026) Analysis & Trends
Immunome (IMNM) has 7 years of Assets Average data on file, last reported at $651.5 million in Q1 2026.
- Quarterly Assets Average rose 123.52% year-over-year to $651.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $651.5 million (up 123.52% YoY) and the FY2025 annual result came in at $461.7 million, up 137.52% from the prior year.
- Assets Average improved to $651.5 million in Q1 2026, from $491.3 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $651.5 million in Q1 2026 to a low of $27.3 million in Q4 2022.
- A 5-year average of $208.6 million and a median of $234.1 million in 2024 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average sank 54.69% — and 2024, when it jumped 587.86%.
- Tracing IMNM's Assets Average over 5 years: stood at $27.3 million in 2022, then soared by 342.74% to $120.9 million in 2023, then jumped by 105.68% to $248.6 million in 2024, then jumped by 97.64% to $491.3 million in 2025, then surged by 32.61% to $651.5 million in 2026.
- The last three Assets Average figures came in at $651.5 million (Q1 2026), $491.3 million (Q4 2025), and $297.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Immunome | 3.09 Bn | 2.57 Bn | - | 592.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 592.59 Mn |
| Mar 31, 2026 | 651.49 Mn |
| Dec 31, 2025 | 491.28 Mn |
| Sep 30, 2025 | 297.83 Mn |
| Jun 30, 2025 | 319.49 Mn |
| Mar 31, 2025 | 291.47 Mn |
| Dec 31, 2024 | 248.57 Mn |
| Sep 30, 2024 | 276.56 Mn |
| Jun 30, 2024 | 307.98 Mn |
| Mar 31, 2024 | 234.15 Mn |
| Dec 31, 2023 | 120.85 Mn |
| Sep 30, 2023 | 67.30 Mn |
| Jun 30, 2023 | 44.77 Mn |
| Mar 31, 2023 | 36.08 Mn |
| Dec 31, 2022 | 27.30 Mn |
| Sep 30, 2022 | 34.78 Mn |
| Jun 30, 2022 | 43.37 Mn |
| Mar 31, 2022 | 52.83 Mn |
| Dec 31, 2021 | 60.24 Mn |
| Sep 30, 2021 | 63.35 Mn |